LITS - NASDAQ

Lite Strategy, Inc.

LITS·NASDAQ

$1.43

-3.5%

HealthcareBiotechnology

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$52.60M

EPS-2.3900

P/E Ratio-1.89

Earnings Date02/11/2026

lits

Net Change in Cash

Last Annual Value

14.31M

3-Year CAGR

26%

5-Year CAGR

42%

10-Year CAGR

19%

Adjust for Inflation

Lite Strategy, Inc. Competitors Analysis of Net Change in Cash

LITS · NASDAQ

Company	Net Change in Cash	CAGR 3Y	CAGR 5Y	CAGR 10Y
Lite Strategy, Inc. NASDAQ:LITS	14.31M	130.6%	N/A	N/A
Relmada Therapeutics, Inc. NASDAQ:RLMD	-360.49K	N/A	N/A	N/A
TScan Therapeutics, Inc. NASDAQ:TCRX	-26.28M	N/A	N/A	N/A
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV	1.69M	-36.3%	-55.6%	N/A
Clene Inc. NASDAQ:CLNN	-6.97M	N/A	N/A	N/A
Prelude Therapeutics Incorporated NASDAQ:PRLD	21.97M	N/A	N/A	N/A
Unicycive Therapeutics, Inc. NASDAQ:UNCY	3.06M	-30.9%	-28.7%	N/A
Vaxart, Inc. NASDAQ:VXRT	28.59M	N/A	11.1%	N/A
Adicet Bio, Inc. NASDAQ:ACET	-17.61M	N/A	N/A	N/A
PMV Pharmaceuticals, Inc. NASDAQ:PMVP	-2.89M	N/A	N/A	N/A
Werewolf Therapeutics, Inc. NASDAQ:HOWL	-54.26M	N/A	N/A	N/A

Lite Strategy, Inc. Fair Value Envelope

LITS · NASDAQ

Our analysis suggests that LITS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.43, this represents a potential HIDDEN relative to our calculated worth for Lite Strategy, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.43

Related Guides

Blog Categories

Continue your LITS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.